key: cord-0820996-ji2ud6td authors: Rao, Vishal; Arakeri, Gururaj; Madikeri, Gaurav; Shah, Ashwin; S Oeppen, Rachel; A Brennan, Peter title: Post-COVID Mucormycosis in India: A formidable challenge date: 2021-06-29 journal: Br J Oral Maxillofac Surg DOI: 10.1016/j.bjoms.2021.06.013 sha: 4183d786c114f4d95710c0bda4b3932ceb271f76 doc_id: 820996 cord_uid: ji2ud6td Together with the ongoing serious Covid-19 second wave in India, a serious fungal infection, mucormycosis has been increasingly found in Covid-19 recovered patients. Colloquially known as “black fungus”, mucormycosis commonly causes necrosis in the head and neck region including the nose, paranasal sinuses, orbits, facial bones, with possible intracranial spread. The disease causes high morbidity and mortality given that diagnosis is often delayed, and that is progresses rapidly. Given the sheer magnitude of the outbreak, the Indian Health Ministry has advised all states to declare mucormycosis an epidemic. Typically, the disease has been found linked to COVID-19 infections caused by the B.1.617.2 (Delta) variant which has spread rapidly throughout India. This variant has already become a cause for global concern, having spread to at least 40 countries, including the USA, and UK. We present the findings of a study conducted on post-COVID Mucormycosis patients and discusses the associated risk factors to raise awareness for OMFS colleagues. While India has not been able to actively control and limit the second wave of COVID-19 1 , the number of new cases is now in decline. 2 Despite this, emerging complications associated with COVID-19 are being reported with the fungal infection mucormycosis becoming a serious issue in India due to its unprecedent surge and high morbidity. [3] [4] Mucormycosis, colloquially known as "black fungus" in India, is a fungal infection caused by the Mucormycetes family of moulds, which are widespread organic matter decomposers found in soil and dust. Mucormycetes is a fungus with at least 20 pathogenic species divided into 12 genera. Rhizopus is the genus that has been linked to the most mucormycosis cases in the literature. 5 Mucormycosis occurs relatively commonly in patients with certain predisposing medical conditions such as immunosuppression and diabetic ketoacidosis. 6 Mucormycosis infiltrates the vascular lamina, causing infarction and necrosis as well as inflammation. 7 Progressive tissue necrosis can occur at different anatomical sites depending on how fungal exposure takes place. This can be through inhalation, ingestion, direct contact or traumatic innoculation. 6 It affects the head and neck, respiratory and central nervous systems, the gastrointestinal tract, and other areas. Rhino-cerebral mucormycosis affects the head and neck, with the most common site being the nose, but the disease can spread to the paranasal J o u r n a l P r e -p r o o f sinuses, orbit, facial bones and cranial cavity. 8 Loose teeth, gingival abscess, and dental extraction are often the first symptoms presenting to OMFS. Mucormycosis in the bone marrow may promote fungal growth by damaging the endothelial lining of vessels, resulting in vascular insufficiency, leading to bone necrosis and fungal osteomyelitis. This complication is more aggressive than the more commonly seen bacteria associated osteomyelitis. 8 The angio-invasive nature of mucormycosis characterized by thrombosing vasculitis and its role in host invasion has been attributed to increased expression of platelet derived growth factor (PDGFRB) signalling. 9 Fatality rates for severe Mucormycosis infections can be close to 100% despite various active treatments. 6 When mucormycosis is suspected, adequate imaging to document the extent of the disease is strongly advised, followed by surgical debridement. The use of high-dose liposomal amphotericin B as a first-line treatment is strongly suggested, whereas intravenous isavuconazole and intravenous or delayed-release tablet posaconazole have also been advocated. 10 Following a sharp rise in the number COVID-19 patients infected with Mucormycosis, the Indian Health Ministry has advised all States to declare Mucormycosis itself an epidemic. 3 Social media and the press contain anecdotal and speculative reports about the cause of Mucormycosis. Various risk factors like long-term use of steroids, antibiotic multivitamins, and zinc have been linked with its incidence. 11 Further, mucosal erosion secondary to aggressive use of steam inhalation or the use of high flow oxygen have also been considered as factors promoting fungus colonisation. 11 Contamination from the use of industrial oxygen, low-quality oxygen cylinders, low-quality oxygen piping system and ordinary tap water in ventilators are also being cited as causative factors. 11, 12 Additionally, COVID is known to cause hyperglycaemia in some patients, which could predispose to fungal infection. 13 To further explore the risk factors, we studied the available data of Post-COVID-19 Mucormycosis patients from the Bengaluru and Kalaburagi (Gulbarga) regions of India . We obtained data from Post-COVID Mucormycosis patients in India's Bengaluru and Kalaburagi districts. Patients whose disease had not been established histopathologically were excluded from the study. We collected information such as age, gender, diabetes mellitus status, hypertension, any existing immunocompromised conditions, time duration for reporting diseases after COVID-19 treatment, vaccination history, use of oxygen and/or ventilator support, steroid, multivitamin, and zinc medications. The data was tabulated and examined for the presence of any risk factors. Twenty eight patients presented to OMFS, with a mean age of 49.1 (SD 10.8) years. Twenty patients (71%) were aged between 41-60 years. Most patients were male (n=22) and the major co-morbidities were diabetes mellitus in 27 patients (96%) followed by hypertension (eight patients). Uncontrolled diabetes was found in 19 patients (68%). Only 13 patients (46%) had steroid therapy, with four of these (14%) given steroids for more than 10 days. Oxygen was used in 17 patients (61%) but only one required ventilator support. The interval between COVID-19 recovery and first reporting of patient for Mucormycosis was more than 15 days in 10 (36%) patients followed by 10 to 14 days in eight patients (28%). Only two patients had received COVID vaccinations, Half of the patients (14) in our series presented with both Mucormycosis pansinusitis and maxillary osteomyelitis (Figure 1 and 2) while in a another six (21%) (21.4%), n=6) it presented as maxillary osteomyelitis functional endoscopic sinus surgery (FESS) for necrotic tissue debridement. We have found that middle aged COVID-19 patients with diabetes mellitus who received steroids were prone to Mucormycosis. The COVID-19 outbreak emphasises the need to understand the complex pathophysiology of diabetes and other diseases. Pathological changes in the pancreas, were observed in patients with severe COVID-19, indicating that SARS-CoV-2 can cause pancreatic injury. 13 This could be one of the reasons why COVID-19 patients who do not have a history of diabetes have higher blood glucose levels. 13, 14 The most common cause of drug-induced hyperglycemia is steroids. 15 They aggravate hyperglycemia in patients with known diabetes mellitus (DM). Diabetes-related J o u r n a l P r e -p r o o f hyperglycemia is thought to cause immune response dysfunction, resulting in diabetic subjects' inability to control the spread of invading pathogens. 16 Diabetes mellitus, when combined with the SARS COV 2 Virus and steroid therapy, appears to cause a vicious cycle of hyperglycemia and immunosuppression, which can lead to severe fungal colonization like mucormycosis. Typically, the disease is seen during the COVID-19 recovery period suggesting that multiple factors facilitate fungal colonization. The time interval between COVID-19 and initial Mucormycosis diagnosis in most of the cases in our series was 10 -15 days. Patients may have overlooked the symptoms of Mucormycosis (especially pain) confusing it with the residual COVID-19 symptoms and therefore presented late to the hospital. Furthermore, we observed that dental symptoms ( Figure 3) were not addressed at initial hospital visits, and priority was given to nasal or sinus symptoms with MRI imaging only. Eventually patients presented with advanced maxillary disease in later follow-up stage (1-3 weeks). It is important to evaluate maxillary bone involvement CT at an early stage, in an attempt to limit tissue necrosis. If both nasal and maxillary disease are found jointly, it is easier to operate on the maxilla first ( Figure 4 ) which provides better and additional endoscopic access for nasal disease clearance through the maxillary sinus. Since only two patients in our series had been vaccinated, this confirms the vital role of the COVID-19 vaccine in reducing serious virus complications and co-morbidity, including Mucormycosis infections. The second wave of COVID-19 in India has led to more deaths than the first. 17 In just a few weeks, the B.1.617.2 (Delta) variant became the dominant strain across India. It has since spread to about 40 nations, which include United Kingdom, Fiji and Singapore. 18 The first J o u r n a l P r e -p r o o f case of Covid-19-related Mucormycosis has now been found in Chile. 19 It is important to recognise at an early stage this infection, so as to potentially reduce soft and hard tissue necrosis and severe complications and alert colleagues of this mutilating and life threatening infection. Ethics approval N/A. Patient permission obtained Experts criticise India's complacency over COVID-19 COVID-19 UPDATE. Ministry of Health and Family Welfare HFW/COVID States data/27thMay2021/1 Additional 29,250 vials of Amphotericin-B allocated to States/UTs 19,420 vials of Amphotericin-B were allocated on 24th May Mucormycosis -a serious threat in the COVID-19 pandemic? Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species Mucormycosis outbreak associated with hospital linens Rise of the phoenix: Mucormycosis in COVID-19 times Maxillofacial Infections in Covid-19 Era-Actuality or the Unforeseen: 2 Case Reports Mucormycosis originated total maxillary and cranial base osteonecrosis: a possible misdiagnosis to malignancy Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium Mucormycosis in COVID-19 patients: What are the risk factors other than diabetes and steroid use Dangerous cocktail of antibiotics, steroids, excessive steam leading to surge in black fungus cases? Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Type 2 Diabetes and its Impact on the Immune System India's resurgence of COVID-19: urgent actions needed Coronavirus variants are spreading in India -what scientists know so far Chile detects first case of Covid 'black fungus' ;The Times We would like to express our gratitude to Sudhir Raikar, Pune and Ramesh Patil, Solapur for their essential assistance in performing the research and preparing the manuscript.